PMID- 35510270
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1177-5467 (Print)
IS  - 1177-5483 (Electronic)
IS  - 1177-5467 (Linking)
VI  - 16
DP  - 2022
TI  - Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of 
      Glaucoma and Ocular Hypertension.
PG  - 1261-1279
LID - 10.2147/OPTH.S340386 [doi]
AB  - Current therapeutic approaches for glaucoma aim to reduce intraocular pressure 
      (IOP), which is the only available and reliable strategy proven to control the 
      risk of disease development and progression. Omidenepag isopropyl (OMDI) is a 
      novel topical ocular hypotensive agent that was launched onto the market for the 
      treatment of glaucoma and ocular hypertension (OHT). After topical instillation 
      and during corneal penetration, OMDI is converted into the active metabolite 
      omidenepag (OMD), which behaves as a non-prostaglandin, selective E-prostanoid 
      subtype 2 (EP2) receptor agonist. The topical administration of 0.002% OMDI 
      once-daily (QD) possesses a 20-35% IOP-lowering effect, comparable to that of 
      prostaglandin analogs targeting F-prostanoid (FP) receptor QD, which are the 
      current first-line for pharmaceutical reduction of IOP. However, the mechanism of 
      action and adverse events (AEs) of OMDI are different from those of FP receptor 
      agonists. OMDI reduces IOP by enhancing both conventional trabecular and 
      uveoscleral outflow facilities without complications of prostaglandin-associated 
      periorbitopathy (PAP) seen with FP receptor agonists. Moreover, OMDI was also 
      effective and well-tolerated in non-/poor responders to latanoprost and showed a 
      stable IOP-lowering effect for one year, and its concomitant use with timolol 
      enhanced the IOP-lowering effect. OMDI demonstrated acceptable safety and 
      tolerability with good adherence and can be used in almost every patient. 
      However, OMDI has some AEs such as conjunctival hyperemia, corneal thickening, 
      macular edema/cystoid macular edema and ocular inflammation. Moreover, OMDI is 
      contraindicated in patients who are allergic to the product, in aphakic or 
      pseudophakic eyes, and in combination with tafluprost eye drops. If used 
      appropriately in the right patients, OMDI could be an effective treatment option 
      for glaucoma and OHT as a first-line alternative to FP agonists. Here, we 
      summarize the results of clinical studies of OMDI and discuss its efficacy and 
      patient tolerability in glaucoma and OHT in this review.
CI  - (c) 2022 Matsuo et al.
FAU - Matsuo, Masato
AU  - Matsuo M
AUID- ORCID: 0000-0001-5261-669X
AD  - Department of Ophthalmology, Shimane University Faculty of Medicine, Izumo City, 
      Shimane, 693-8501, Japan.
FAU - Matsuoka, Yotaro
AU  - Matsuoka Y
AD  - Division of Ophthalmology, Matsue Red Cross Hospital, Matsue, Shimane, 690-8506, 
      Japan.
FAU - Tanito, Masaki
AU  - Tanito M
AD  - Department of Ophthalmology, Shimane University Faculty of Medicine, Izumo City, 
      Shimane, 693-8501, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220426
PL  - New Zealand
TA  - Clin Ophthalmol
JT  - Clinical ophthalmology (Auckland, N.Z.)
JID - 101321512
PMC - PMC9058248
OTO - NOTNLM
OT  - EP2 receptor
OT  - adverse event
OT  - glaucoma
OT  - intraocular pressure
OT  - omidenepag
OT  - prostaglandin
COIS- Santen Pharmaceutical Co., Ltd. provided information on the status of latest 
      clinical trials of OMDI and assisted us in the preparation of Figures 1 and 2. No 
      involvement was made in the writing or reviewing. The authors report no conflicts 
      of interest in this work.
EDAT- 2022/05/06 06:00
MHDA- 2022/05/06 06:01
PMCR- 2022/04/26
CRDT- 2022/05/05 02:39
PHST- 2022/01/23 00:00 [received]
PHST- 2022/04/14 00:00 [accepted]
PHST- 2022/05/05 02:39 [entrez]
PHST- 2022/05/06 06:00 [pubmed]
PHST- 2022/05/06 06:01 [medline]
PHST- 2022/04/26 00:00 [pmc-release]
AID - 340386 [pii]
AID - 10.2147/OPTH.S340386 [doi]
PST - epublish
SO  - Clin Ophthalmol. 2022 Apr 26;16:1261-1279. doi: 10.2147/OPTH.S340386. eCollection 
      2022.